Press Release: Novartis Kisqali(R) reduces risk -3-

site from the Phase III MONALEESA-2 study of first-line ribociclib +

letrozole in postmenopausal patients with HR+/HER2- advanced breast

cancer. Presented at the San Antonio Breast Cancer Symposium, December

7-10, 2021. Texas, USA.

22. European Society of Medical Oncology (ESMO). ESMO MCBS scorecards;

NATALEE. Accessed May 2025.

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-468-1

23. European Society for Medical Oncology. Magnitude of Clinical Benefit

Scale Scorecard. Accessed May

2025. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumou

rs/esmo-mcbs-scorecards?scorecard=158-1

24. European Society for Medical Oncology. Magnitude of Clinical Benefit

Scale Scorecard. Accessed May

2025. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumou

rs/esmo-mcbs-scorecards?scorecard=9-1

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 3247944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

June 01, 2025 09:00 ET (13:00 GMT)